# US 2012/0251537 A1 · Compositions and methods for the treatment of infections and tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251537 A1
- Document ID: US20120251537A1
- Status: Published application
- Kind: A1
- Application number: 13/436,492
- Filed: 2012-03-30
- Published: 2012-10-04
- Earliest claimed: 2006-12-27
- Assignees: Emory University; President and Fellows of Harvard College; Dana-Farber Cancer Institute, Inc.
- Inventors: Rafi Ahmed; Rama Amara; Gordon Freeman; Arlene Sharpe
- Web page: https://patentgrep.com/patent/US20120251537A1

## CPC

- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61K 39/12: Viral antigens
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/36: Immune checkpoint inhibitors
- A61K 40/46: Viral antigens
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/06: for tuberculosis
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/18: for HIV
- A61P 31/20: for DNA viruses
- A61P 31/22: for herpes viruses
- A61P 33/00: Antiparasitic agents
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P 33/06: Antimalarials
- A61P 33/14: Ectoparasiticides, e.g. scabicides
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/2818: {against CD28 or CD152}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61K 2039/5256: {expressing foreign proteins}
- C07K 2317/64: comprising a combination of variable region and constant region components
- C12N 2710/24143: viral genome or elements thereof as genetic vector
- C12N 2740/16011: Human Immunodeficiency Virus, HIV
- C12N 2760/10011: Arenaviridae
- C12N 2760/10034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/24211: Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In addition, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist.

## Claims

### Claim 1

A method of treating a subject with a persistent infection of a pathogen, comprising administering to the subject a therapeutically effective amount of a Programmed Death (PD-1) antagonist and an effective amount of a therapeutic vaccine, thereby treating the persistent infection in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the pathogen is a virus, and wherein the subject has a persistent viral infection.

### Claim 3 (depends on 2)

The method of claim 2, wherein the therapeutic vaccine comprises a viral antigenic peptide or a nucleic acid encoding the viral antigenic peptide.

### Claim 4 (depends on 1)

The method of claim 1, wherein the PD-1 antagonist is an antibody that specifically binds PD-1, an antibody that specifically binds Programmed Death Ligand 1 (PD-L1) or Programmed Death Ligand-2 (PD-L2), or combinations thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein the subject is immunosuppressed.

### Claim 6 (depends on 2)

The method of claim 2, wherein the PD-1 antagonist is an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-PD-L2 antibody, a small inhibitory anti-PD-1 RNAi, a small inhibitory anti-PD-L1 RNA, a small inhibitory anti-PD-L2 RNAi, an anti-PD-1 antisense RNA, an anti-PD-L1 antisense RNA, an anti-PD-L2 antisense RNA, a dominant negative PD-1 protein, a dominant negative PD-L1 protein, or a dominant negative PD-L2 protein.

### Claim 7 (depends on 4)

The method of claim 4, wherein the antibody that specifically binds PD-1, the antibody that specifically binds PD-L1, and/or the antibody that specifically binds PD-L2 is (1) a monoclonal antibody or an antigen binding fragment thereof, (2) a humanized antibody or an antigen binding fragment thereof, or (3) an immunoglobulin fusion protein.

### Claim 8 (depends on 2)

The method of claim 2, wherein the subject is asymptomatic.

### Claim 9 (depends on 2)

The method of claim 2, wherein the virus is a human T-Cell leukemia virus, an Epstein-Barr virus, a cytomegalovirus, a herpesvirus, a varicella-zoster virus, a papovavirus, a hepatitis virus, an adenovirus, a parvovirus or a papillomavirus.

### Claim 10 (depends on 2)

The method of claim 2, wherein the virus is a human immunodeficiency virus, a hepatitis C virus, an Epstein-Barr Virus, or a cytomegalovirus.

### Claim 11 (depends on 10)

The method of claim 10, wherein the subject is human.

### Claim 12 (depends on 2)

The method of claim 2, further comprising measuring the proliferation of virus specific CD8+ T cells in a biological sample from the subject.

### Claim 13 (depends on 2)

The method of claim 2, wherein the PD-1 antagonist is an antibody that specifically binds PD-L1.

### Claim 14 (depends on 13)

The method of claim 13, wherein the persistant infection is an infection with a human immunodeficiency virus.

### Claim 15 (depends on 14)

The method of claim 14, wherein the antigen is gp41 or gp120.

### Claim 16 (depends on 13)

The method of claim 13, wherein the persistent infection is an infection with hepatitis c virus.

### Claim 17 (depends on 16)

The method of claim 16, wherein the antigen is Hepatitis C virus (HCV) E1, E2 or a core protein.

### Claim 18 (depends on 2)

The method of claim 2, wherein the therapeutic vaccine is a heat-killed vaccine, an attenuated vaccine, or a subunit vaccine.

### Claim 19 (depends on 2)

The method of claim 2, wherein the therapeutic vaccine comprises an adjuvant.
